Skip to main content
Transcode Therapeutics, Inc. logo

Transcode Therapeutics, Inc. — Investor Relations & Filings

Ticker · RNAZ ISIN · US89357L1052 US Professional, scientific and technical activities
Open in API
Filings indexed 283 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country US United States of America
Listing US RNAZ

About Transcode Therapeutics, Inc.

https://www.transcodetherapeutics.com/

Transcode Therapeutics, Inc. is a clinical-stage oncology company developing RNA-based therapeutics for metastatic cancer. The company's strategy focuses on the specific eradication of metastatic tumor cells by targeting microRNA-10b (miRNA-10b), identified as a master regulator of metastasis. Its lead therapeutic candidate, TTX-MC138, is an oligonucleotide designed to inhibit miRNA-10b. Transcode utilizes a proprietary iron oxide nanoparticle delivery platform, TTX, to transport its therapeutic candidates to tumor sites. Pre-clinical studies in murine models have demonstrated that TTX-MC138 can induce regression of established metastases in breast and pancreatic cancers. The company's approach has potential applicability across numerous cancer types where miRNA-10b is involved, including breast, pancreatic, ovarian, and colon cancers, as well as glioblastomas.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 78% confidence The document is a U.S. SEC Form 8-K “Current Report” under the Securities Exchange Act of 1934, reporting an “Other Events” Item 8.01 and attaching a press release as Exhibit 99.1. It does not itself contain financial statements or earnings data, nor is it an earnings release, management change, or other specific report type. As a generic regulatory filing, it falls into the fallback category “Regulatory Filings” (RNS).
2026-06-03 English
DEF 14A
Proxy Solicitation & Information Statement
2026-06-02 English
ARS
Annual Report
2026-06-02 English
FORM 8-K
Regulatory Filings Classification · 87% confidence The document is a Form 8-K (“Current Report”) filed under the Securities Exchange Act, specifically Item 5.08 concerning shareholder nominations for the 2026 Annual Meeting. It does not contain substantive financial statements, proxy materials themselves, or detailed report content, but is a regulatory announcement of these governance-related deadlines. This falls under the general Regulatory Filings category (RNS).
2026-06-01 English
DEFA14A
Proxy Solicitation & Information Statement
2026-05-26 English
FORM 8-K/A
Delisting Announcement Classification · 88% confidence The document is an Amendment No. 1 to a Current Report on Form 8-K (an SEC ‘8-K/A’) whose sole substantive Item (Item 3.01) is a Notice of Nasdaq deficiency letter and potential delisting/failure to satisfy a continued listing rule. This falls squarely under the “Delisting Announcement” category (code DLST).
2026-05-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.